Background: Sanger sequencing of plasma RNA is the standard method for HIV-1 drug resistance testing in treatment-naive patients, but is limited by the non-detection of resistance-associated mutations (RAMs) with prevalence below approximately 20%.
Introduction
The presence of baseline drug resistance-associated mutations (RAMs) in patients newly diagnosed with HIV infection is associated with impaired outcomes of first-line ART.
1,2 Therefore guidelines in most developed countries recommend drug resistance testing in persons with HIV infection at entry into care. 3 Data on drug resistance are useful to guide clinicians in the choice of firstline regimen with the highest likelihood of virological response. Furthermore, drug resistance testing in ART-naive patients provides information on resistance transmission that is essential for treatment policy formulation. 4 Genotypic testing using plasma HIV RNA is the standard approach recommended in treatment-naive HIV patients and usually includes testing for mutations in the reverse transcriptase (RT), protease (PR) and integrase (IN) genes. Drug resistance testing can also be performed using HIV-DNA archived in cells, but this is not recommended for routine use when plasma RNA viral load is high enough for optimal sequencing. Cell-associated HIV-DNA is believed to better reflect viral diversity and may increase the chances of identifying RAMs. 5 Previous studies have investigated RNA and DNA sequencing for HIV drug resistance testing and have reported conflicting results, depending on patients' profiles. Indeed, DNA was shown to provide additional resistance information in ART-naive patients, [6] [7] [8] while this approach was less sensitive in treatment-experienced patients. [9] [10] [11] In addition, interpretation of DNA-based resistance data is challenged by the potential for interference from defective, replication-incompetent proviruses. These variants may result from the activity of APOBEC3 proteins, a host defence component, through a hypermutation process. 12, 13 Sanger bulk sequencing is the most common approach used for HIV drug resistance testing in clinical settings. However, it is well known that this method only detects variants with prevalence .20%. 14, 15 Minority HIV-1 drug resistance mutations have been described in ART-naive populations and were shown to potentially V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
impact treatment outcome. [16] [17] [18] [19] [20] Next-generation sequencing (NGS) assays have the advantage of allowing detection of minority variants with a threshold as low as 1%. 21, 22 In clinical laboratories, several algorithms are available for routine HIV drug resistance interpretation; however, predictions may significantly differ between these algorithms. 23 In the present study, we compared RNA and DNA Sanger sequencing (RSS and DSS) with RNA NGS for the detection of RAMs in HIV-1 RT, PR and IN genes and examined three different algorithms for drug resistance interpretation. In addition, the potential impact of minority resistance mutations on the short-term treatment outcome was analysed.
Patients and methods

Patients and samples
This study included HIV-1-infected patients followed at the Infectious Diseases department of Tourcoing general hospital (northern France). From October 2013 to June 2015, treatment-naive patients, who underwent initial drug resistance testing, with both EDTA plasma and whole blood samples available, were included in the study. Resistance analysis through RSS of the RT, PR and IN genes was performed as part of routine laboratory monitoring of these newly diagnosed patients. DSS and RNA NGS were performed retrospectively. Demographics and clinical data of patients were retrospectively collected from the NadisV R database.
Ethics
All subjects signed the ethics board-approved informed consent form of the HIV NadisV R electronic patient record database.
Nucleic acid extraction
RNA extraction was performed on 140 lL of EDTA plasma using the Qiamp viral RNA mini kit (Qiagen, Courtaboeuf, France). Total DNA was extracted from 200 lL of whole blood using the Nucleospin Blood kit (Macherey Nagel, Hoerdt, France).
Viral load (VL) quantification
Plasma VL determination was done with Cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0 (Roche). The quantification of total HIV-1 DNA was performed on whole blood using a real-time PCR assay (Biocentric, Bandol, France), as previously described. 24 DNA extracts from whole blood were tested in three replicates. The real-time PCR result was expressed as copies/10 6 leucocytes and then converted in copies/10 6 PBMCs, using the white blood cell differential count.
Sanger sequencing
Sanger bulk sequencing was performed on both RNA and DNA. Amplifications were based on primers and protocols provided by the French National Agency for AIDS Research (ANRS). Sequencing products were analysed on a 3500Dx genetic analyser (Applied Biosystems). Electropherograms were manually edited with Seqscape software version 3 (Thermo Fisher Scientific). Data generated from Sanger sequencing (fasta format) were transferred to ViroScore software (ABL) for mutation analysis.
Next-generation sequencing
NGS was performed on plasma RNA using the four-plate HIV-1 Drug Resistance Assay-Collaboration Initiative version 3.0 (Roche) on a 454 GS Junior next-generation sequencer (Roche), according to the manufacturer's instructions. Briefly, extracted RNA was purified with Agencourt RNA Clean XP beads (Beckman Coulter). Reverse transcription was carried out using the Transcriptor First Strand cDNA Synthesis Kit (Roche) and the cDNA primer plate, containing a dried-down primer. Then, cDNA was treated with RNase H (Roche). PCR amplification was performed using the FastStart High Fidelity PCR System and the amplicon primer plate containing dried-down primers for four amplicon sets in the RT and PR genes (RTP_A, B, C and D) and one amplicon in the IN gene (INT_X). The expected sizes for amplicons were as follows: 400 bp for RTP_A, 418 bp for RTP_B, 432 bp for RTP_C, 434 bp for RT_D, and 503 bp for INT_X. Primers were extended with amplicon adaptor sequences and different Roche multiplex identifier (MID) tags, allowing analysis of up to 10 samples and 2 controls in the same run. PCR products were subsequently purified using Agencourt AMPure XP beads (Beckman Coulter) and quantified by fluorometry using the Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen). Amplicons were evaluated by 1.5% gel electrophoresis, with a band expected around 400-500 bp. Thereafter, amplicons were diluted to an equimolar concentration of 10 9 molecules/lL and pooled. The DNA pool was then purified twice, quantified once again, and finally a 10 6 molecules/lL amplicon pool was prepared for sequencing. Amplicons were added to DNA capture beads at a ratio of two molecules per capture bead, and emulsion PCR was performed using the Lib-A emPCR kit (Roche). Then, DNA library bead enrichment was carried out and a 200 cycle sequencing was run on the Roche 454 GS Junior system according to the manufacturer's instructions. Amplicons were sequenced from forward and reverse ends.
Data processing and quality filtering were performed using the instrument AVA software and HIV script. Variant frequencies were determined with insertions/deletions and homopolymer correction scripts. Then, data were imported and analysed in DeepCheck software (ABL). Stringent quality criteria were applied by the DeepCheck HIV expert system to filter irrelevant mutations. There are at least four major filters, including noisy mutation filtering (used to remove low-frequency mutations that are usually the product of sequencing noise instead of real mutations), coverage filtering, forward/reverse unbalanced frequency, forward/reverse unbalanced coverage. Only mutations that pass the expert system are used for drug interpretation. The expert system also determines the minimum number of reads needed for the different prevalence thresholds selected for the analysis. The minimum number of sequences to guarantee, at the 99% confidence level, that all mutations with the given threshold frequency have been found at that position, was 23, 92 and 461 for 20%, 5% and 1% thresholds, respectively.
Analysis of hypermutation
Identification of hypermutation was performed with Hypermut 2.0 software using default settings. 25 To investigate G-to-A substitutions, each HIV-1 sequence was aligned with a reference sequence. HXB2 was used as the reference sequence for RNA sequences, and for DNA sequences, the matched-RNA sequence was used as reference. Sequences were considered hypermutated if a P , 0.05 was obtained in a Fisher's exact test that compared the number of G-to-A changes in APOBEC3 versus control contexts. 
Identification of mutations and drug resistance interpretation
Statistical analysis
Patient characteristics were presented as median with IQR or as percentages. The mutation detection rate was compared between RSS, DSS and RNA NGS 20%, using the paired t-test. P , 0.05 was considered significant. All calculations were performed using Graphpad Prism version 6 software (La Jolla, CA, USA).
Results
Patients and sequences
HIV resistance genotyping (RT, PR, IN genes) was successfully performed with the three sequencing approaches in 48 treatmentnaive patients. The patient characteristics are described in Table 1 . The median age was 36.5 years old and patients were mainly male (87.5%). Most of the patients were infected by a subtype B virus (70.8%), and samples were collected within 10.5 days after the diagnosis of HIV infection. At the time of sampling, CD4 T cell count and plasma VL were 351.5 cells/mm 3 and 4.9 log 10 copies/mL respectively. The median HIV DNA VL was 3.6 log 10 copies/10 6 PBMCs. A good quality and coverage was obtained for all Sanger sequences. Hypermutation was not detected in RNA sequences. Two DNA sequences (one RT and one PR) were found to be hypermutated. In deep sequencing, the average length of reads was 375 bp, and the total number of reads ranged between 77000 and 100000 for each run including 10 samples. The median number of reads per patient and per nucleotide position was 760, 455 and 399 for RT, PR and IN, respectively, and did not allow accurate detection of variants down to a frequency of 1% for all patients. Therefore 20% and 5% thresholds were used for analysis at a confidence level of 99% according to requirements described in the Patients and methods section.
Resistance-associated mutations
According to the IAS-USA mutations list, the number of cumulative RAMs (RT, PR, IN) in all patients was 197, 199, 233 and 319 with RSS, DSS, NGS 20% and NGS 5%, respectively; however, most of these were minor mutations in the PR gene. The number of patients with a least one major RAM was 3, 5, 4 and 8 when using RSS, DSS, NGS 20% and NGS 5%, respectively. After hypermutation clean-up for DSS, the number of RAMs was 193, and 3 patients had at least one major RAM (Table 2) .
Mutations associated with resistance to NRTIs
Overall, very few patients with RAMs associated with NRTIs were observed with RSS, DSS and NGS 20% (1, 2 and 2, respectively). The number of patients increased to 4 with NGS 5%. L210W was the only mutation detected by all methods: in 1 patient with RSS and DSS, in 2 patients with NGS 20%, and in 3 patients with NGS 5%. M184I was found in one hypermutated DNA RT sequence but was not confirmed on RNA sequences. NGS 5% allowed detection of additional mutations such as M41L and L74V as shown in Figure 1 (a).
Mutations associated with resistance to NNRTIs
Major RAMs to NNRTI were detected in 2, 3, 2 and 3 patients using RSS, DSS, NGS 20% and NGS 5%, respectively. E138A was the only major mutation detected by all methods. E138K and M230I were observed in the same hypermutated DNA RT sequence with the M184I mutation. A few minor mutations, including V90I, A98G and V106I, were also detected (see Figure 1b) .
Mutations associated with resistance to PIs
No major RAM to PIs was observed in any patients with RSS and NGS 20%. D30N and M46I were detected in a hypermutated DNA PR sequence. NGS 5% allowed detection of M46I and N88S in two other patients. Numerous minor mutations were found in protease sequences, and almost all patients harboured at least one minor mutation whatever the sequencing method. The most prevalent minor mutations (present in at least 10% of patients whatever the method) include L10I, G16E, K20I/R, M36I, D60E, I62V, L63P, I64V, H69K, A71T, V77I, L89M and I93L (Figure 1c) . Sequencing methods for HIV-1 drug resistance testing
JAC
Mutations associated with resistance to INSTIs
No major mutation was observed, whatever the method, in the IN gene. Only two minor mutations (L74M and T97A) were found in very few patients (0-3)
Comparison of RAM detection between RSS, DSS and NGS 20%
The mutation detection rate of Sanger methods was compared with that of NGS 20%, since it is well known that the variant detection limit of Sanger sequencing is around 20%. The results are detailed in Table 3 . As compared with RSS, the total number of RAMs was slightly lower with DSS after hypermutation clean-up; however, the overall mutation detection rate was similar between RSS and DSS (P " 0.25). NGS 20% detected a significantly higher number of RAMs, especially in the PR gene (P " 0.004 and 0.003 as compared with RSS and DSS, respectively).
Drug resistance interpretation using different algorithms
The susceptibility patterns to all main antiretroviral molecules were predicted with three algorithms: ANRS, Stanford and Rega. Overall, the susceptibility prevalence to antiretroviral drugs was high (.95%), whatever the algorithm, when analysing data obtained from RSS, DSS and NGS 20%, and decreased with NGS 5%. However, some differences were observed between drug classes as detailed in Table S1 (available as Supplementary data at JAC Online). Profiles were almost comparable for NRTIs and NNRTIs using all algorithms with RSS, DSS and NGS 20% results (susceptibility range between 95.3% and 99%). Predictions with the Stanford algorithm were overall the most affected by NGS 5% (92% and 86.5% of susceptible sequences for NRTIs and NNRTIs, respectively). The number of patients with a virus resistant or intermediate (R/I) to at least one drug ranged from 2 to 8 for NRTIs, and from 2 to 13 for NNRTIs (see Table 4 ). The detailed analysis of antiretroviral molecules is shown in Tables S2 and S3. Regarding PIs, ANRS was clearly the most stringent tool. The proportion ranges of susceptible sequences were as follows: 92.7%-81.7% for ANRS, 99.4%-96.7% for Stanford and 99.4%-95.2% for Rega (see Table S1 ). In addition, the number of patients R/I to at least one molecule was higher with ANRS (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) than with Stanford (2-4) and Rega (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . No sequence was found to be resistant to darunavir/ritonavir whatever the sequencing methods and interpretation tools (See Table S4 ).
Almost all sequences were susceptible to INSTIs. The Stanford algorithm yielded the least favourable results (see Table S1 ), with a proportion of susceptible sequences (97.9%-95.8%) lower than that obtained with ANRS (100%) and Rega (100%-98.6%). Furthermore the number of patients R/I to at least one drug was D60E  I62V  L63P  I64L  I64M  I64V  H69K  A71T  A71V  G73S  V77I  V82I Alidjinou et al.
higher with Stanford (3-5), compared with ANRS (0) and Rega (0-2) (see Table 4 ). Detailed data on the different drugs are provided in Table S5 . Sequences were all susceptible to dolutegravir.
Impact of baseline minority RAMs on the short-term treatment outcome
ART was initiated in all patients within a median delay of 27 days (IQR 13-62 days), based on the results of the routinely performed RSS. The first-line ART regimen initiated was as follows: 2 NRTI ! 1 PI (60.4%), 2 NRTI ! 1 INSTI (25%) and 2 NRTI! 1 NNRTI (14.6%). Follow-up data at 6 months post treatment were available for 45 patients. Six patients did not reach RNA VL suppression at 6 months, and fulfilled virological failure criteria. However, the VL at 6 months for these patients was low (median 75, IQR 51-171 copies/mL). Baseline resistance patterns of the six patients using data from NGS 5% were analysed to search for potential minority RAMs that could be linked with a failure. No resistance was found for drugs used in various ART regimens of these patients. The treatment history and baseline resistance patterns are detailed in Table 5 .
Discussion
The aim of this study was to evaluate the potential of DSS and RNA NGS to detect RAMs in treatment-naive (TN) patients, as compared with the routinely performed RSS. To the best of our knowledge, this is the first report assessing RAMs with these three different approaches in the three main drug-target HIV-1 genes (RT, PR, IN). The prevalence of drug resistance observed with RSS in HIV-1 newly infected patients is highly variable throughout the world and is relatively stable at around 10% in Europe. 4, 26 In addition, the prevalence of virological failure after first-line ART regimen is around 4% in patients with no baseline drug resistance, and 15% in patients with baseline drug resistance. 2 At least a part of this failure may result from pre-existing mutations not detected by RSS. This highlights the need for a more sensitive but clinically relevant method for routine practice.
We used in this study the mutation list developed by IAS-USA for clinical use, which is based on in vitro experiments or susceptibility testing of clinical isolates, 27 and different from the WHO consensus list of drug resistance mutations, which is suitable for surveillance purposes. 28 Very few RAMs were observed in patients using RSS. Overall, a good concordance was found between RSS and DSS. Our findings clearly suggest that DSS does not improve the detection of transmitted drug resistance as compared with RSS in TN patients. DSS was thought to be attractive as an adjunct to RSS because it was reported that some transmitted mutations may disappear from plasma over time. 29 However, DSS may lack sensitivity and specificity. Indeed, few major mutations found in DNA sequences were not confirmed in RNA sequences. These mutations were detected in hypermutated DNA sequences and include M184I, E138K, M46I and D30N. Such mutations can lead to drug resistance misinterpretation and may represent a significant obstacle to the use of DNA sequencing in TN patients. It is well known that defective hypermutated viruses can be found in cells, mainly resulting from activity of APOBEC3 proteins through G-to-A transitions. 13, 30, 31 Dauwe et al. 32 also recently found these mutations only in DNA sequences and produced evidence of hypermutation. Fourati et al. 33 suggested that M184I and E138K are highly prevalent in the proviral reservoir prior to drug exposure, as a result of APOBEC3 editing. Number after hypermutation clean-up. 
JAC
In this study, we found a more frequent detection of RAMs using NGS, and NGS 20% was even more sensitive than RSS and DSS especially regarding minor mutations associated with resistance to PIs. Several reports have shown increased detection of RAMs using NGS with a threshold below 20% in TN patients. 34, 35 However, caution should be exercised when reporting lowfrequency variants because NGS can generate some errors. One of the most common error modes with 454 technology is the challenge of correctly counting the number of bases in homopolymer runs. The impact of these errors on viral diversity studies can be enormous. 36, 37 Error correction is then important to separate true genetic variation from measurement noise. The 454 technology and the protocols used for NGS in this study are no longer developed.
Low-frequency NNRTI RAMs in ART-naive patients were a particular feature. 38 The impact of pre-treatment resistance associated minority variants on treatment outcomes has been investigated, and these variants have been shown to affect in particular the effectiveness of first-line NNRTI-based regimens. 17, [39] [40] [41] [42] [43] Pre-existing minor resistance mutations were reported to be more prevalent in patients with virological failure to first-line NNRTIbased ART. 44 Increased risk of treatment failure was detected even at very low minority variant frequencies (,0.5% and 10-99 mutant copies/mL). 45 However, TN patients harbouring lowfrequency NNRTI resistance mutations (below 1%) were shown to achieve virological success when they received first-line NNRTIbased ART. 46 These observations highlight the urgent need to determine a clinically relevant cut-off for low-frequency RAMs before implementation of NGS in routine practice. In our study, no virological failure was found to be associated with baseline minority resistant variants, but the frequency of NNRTI in the first-line regimen was low. This finding raises the question of whether minority variants could impact treatment outcome in TN patients not receiving NNRTI, and available data remain controversial. 45 Thus, the benefit of routine NGS use in these patients requires further investigation. Another factor that could also limit routine NGS use is handling preparation especially for library preparation steps, highlighting the need for automation for routine use. In addition, the commercial solutions currently available still need optimization for samples with VL below 2000 copies/mL. After overcoming these obstacles, NGS solutions could be cost effective in routine practice. 21, 47 Finally, we also found differences between the major interpretation algorithms used here, as previously described. 23, 48, 49 These discrepancies are likely to increase with the use of more sensitive methods such as NGS. We highlighted that the ANRS algorithm was the most stringent regarding PIs, while INSTIs were heavily influenced by the Stanford algorithm interpretation.
In conclusion, this study clearly shows that DSS does not improve the detection of RAMs in ART-naive patients, as compared with the routinely used RSS, while NGS significantly increases detection of minority RAMs; however, the clinical relevance of these mutations and the useful threshold need to be further investigated, especially in patients not receiving NNRTIs in their first-line ART regimen.
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